{
    "2021-08-19": [
        [
            {
                "time": "",
                "original_text": "贝达药业：CM082肾癌适应症的新药注册申报准备工作正在推进中，公司会加紧安排，争取新药尽早申报上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "CM082",
                        "肾癌",
                        "新药",
                        "注册申报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：传闻丁董与王博士意见分歧，严重影响公司研发项目进度不实",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "丁董",
                        "王博士",
                        "意见分歧",
                        "研发项目"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：凯美纳术后辅助治疗适应症已于今年6月获批上市，贝伐珠单抗类似物MIL60目前已完成相关核查，力争年内获批上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯美纳",
                        "术后辅助治疗",
                        "贝伐珠单抗",
                        "MIL60",
                        "获批上市"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}